Australian biopharma Clinuvel to shed up to 20% of workforce in move to US

Clinuvel Pharmaceuticals relocates HQ to the U.S. from January 2027 with Nasdaq listing and 10-20% workforce reduction. The move exploits valuation arbitrage: U.S.-listed pharma trades at materially higher enterprise value-to-revenue multiples and accesses deeper capital pools, critical for deeptech scale.